T. Rowe Price Associates
GBT

T. Rowe Price Associates’s Global Blood Therapeutics, Inc. GBT Stock Holding History

T. Rowe Price Associates’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-571,115
Closed -$38.9M – 3054
2022
Q3 		$38.9M Sell
571,115
-2,535,686
-82% -$140M 0.01% 727
2022
Q2 		$99.3M Sell
3,106,801
-74,498
-2% -$2.18M 0.01% 663
2022
Q1 		$110M Sell
3,181,299
-79,386
-2% -$2.37M 0.01% 698
2021
Q4 		$95.4M Sell
3,260,685
-147,309
-4% -$4.56M 0.01% 783
2021
Q3 		$86.8M Sell
3,407,994
-352,201
-9% -$10.4M 0.01% 815
2021
Q2 		$132M Sell
3,760,195
-113,871
-3% -$4.45M 0.01% 689
2021
Q1 		$158M Sell
3,874,066
-189,057
-5% -$8.69M 0.02% 628
2020
Q4 		$176M Sell
4,063,123
-146,011
-3% -$7.2M 0.02% 556
2020
Q3 		$232M Sell
4,209,134
-351,309
-8% -$22.3M 0.03% 451
2020
Q2 		$288M Sell
4,560,443
-492,139
-10% -$33.8M 0.04% 392
2020
Q1 		$258M Sell
5,052,582
-603,603
-11% -$40.4M 0.04% 356
2019
Q4 		$450M Buy
5,656,185
+1,077,160
+24% +$63.8M 0.06% 320
2019
Q3 		$222M Buy
4,579,025
+402,083
+10% +$21M 0.03% 431
2019
Q2 		$220M Buy
4,176,942
+572,808
+16% +$32.9M 0.03% 445
2019
Q1 		$191M Buy
3,604,134
+461,588
+15% +$22.7M 0.03% 484
2018
Q4 		$129M Buy
3,142,546
+154,539
+5% +$5.79M 0.02% 542
2018
Q3 		$114M Buy
2,988,007
+240,410
+9% +$10.6M 0.02% 628
2018
Q2 		$124M Buy
2,747,597
+214,308
+8% +$9.76M 0.02% 603
2018
Q1 		$122M Buy
2,533,289
+601,727
+31% +$33.6M 0.02% 591
2017
Q4 		$76M Buy
1,931,562
+1,264,013
+189% +$47.2M 0.01% 727
2017
Q3 		$20.7M Buy
667,549
+111,723
+20% +$3.14M ﹤0.01% 1172
2017
Q2 		$15.2M Buy
+555,826
New +$16.5M ﹤0.01% 1241
2017
Q1 		– Sell
-342,573
Closed -$4.95M – 2606
2016
Q4 		$4.95M Buy
+342,573
New +$6.02M ﹤0.01% 1423

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates's GBT Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 571,115 shares — an estimated $38.9M sold.

T. Rowe Price Associates first reported a position in GBT in Q4 2016 and held it in 23 quarters. The position peaked at $450M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 571,115 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $38.9M.
  • T. Rowe Price Associates first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 23 quarters.
  • T. Rowe Price Associates's Global Blood Therapeutics, Inc. position peaked at $450M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.